Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Benzodiazepine or Stimulant or [[:Category:Heart_failure_medications|Heart failure medication]]

Use the filters below to narrow your results.

generic:
brand:
None (51) · Benzedrex (1) · Dalmane (1) · Doral (1) · Farxiga (US), Forxiga (international) (1) · Halcion (1) · Jardiance (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1)
classes: (Click arrow to add another value)
mechanism:
None (2) · Adenosine receptor antagonist (1) · Adenosine receptor antagonist; dopaminergic (1) · Adenosine receptor antagonist; phosphodiesterase inhibitor (1) · Alpha-adrenergic agonist; monoamine releaser (1) · Alpha-methylated amphetamine analogue; norepinephrine releasing agent (1) · AMPA modulator; catecholaminergic (1) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Dopamine and serotonin reuptake inhibitor; actoprotector (1) · Dopamine reuptake inhibitor; tropane analogue (1) · Dopamine/norepinephrine reuptake inhibitor (5) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · Indirect sympathomimetic; norepinephrine releaser (1) · Monoamine releasing agent (8) · Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) · Monoamine releasing agent; active ingredient in khat (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Monoamine reuptake inhibitor; sodium channel blocker (1) · N-methyl analogue of 2-AI (1) · Nicotinic acetylcholine receptor agonist (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine releaser (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Norepinephrine–dopamine reuptake inhibitor (2) · Potent dopamine and norepinephrine reuptake inhibitor (1) · Potent dopamine/norepinephrine reuptake inhibitor (1) · Selective norepinephrine reuptake inhibitor (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Trace amine-associated receptor 1 (TAAR1) agonist; monoamine releaser (1)
uses:
None (65) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) · '"`UNIQ--vote-00000278-QINU`"', '"`UNIQ--vote-00000279-QINU`"', '"`UNIQ--vote-0000027A-QINU`"', '"`UNIQ--vote-0000027B-QINU`"' (1) · '"`UNIQ--vote-0000054E-QINU`"', '"`UNIQ--vote-0000054F-QINU`"', '"`UNIQ--vote-00000550-QINU`"', '"`UNIQ--vote-00000551-QINU`"' (1)
starting dose:
None (65) · 0.25 mg (1) · 10 mg PO once daily in the morning; 5 mg starting in heart failure (1) · 10 mg PO once daily in the morning; may titrate to 25 mg for additional glycemic effect (1)
preparations:
None (65) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 10 mg, 25 mg tablets (1) · 5 mg, 10 mg tablets (1)
fda max:
None (65) · 10 mg/d (2) · 25 mg/d (1)
routes:
None (65) · Oral (3)
onset:
None (65) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · Glycosuria within hours; HbA1c effect at 12 weeks; cardiovascular and renal benefits over months (1) · Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months (1)
duration:
None (65) · 24 hours (2) · 6 h (immediate-release); ~11 h (extended-release) (1)
halflife:
None (65) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · ~12.4 hours'"`UNIQ--ref-0000027C-QINU`"' (1) · ~12.9 hours'"`UNIQ--ref-00000552-QINU`"' (1)
bioavailability:
None (65) · 80-90% oral (1) · High (oral; not affected by food, but typically given with the morning meal)'"`UNIQ--ref-0000027D-QINU`"' (1) · ~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' (1)
pregnancy:
None (65) · Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1)
legal:
None (65) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 68 results in range #1 to #68.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"